Kontrol Technologies Corp. is shipping BioCloud units to distributors in Qatar and the Czech Republic, as part of existing distribution agreements, as it continues to expand its BioCloud technology footprint. As communicated to the Company, the final phase of testing is anticipated to be completed in January or February 2022, subject to timelines that are not in the Company's control.

BioCloud is not a medical device and testing is being conducted at the request of various government agencies. Following additional performance testing at the University of Western Ontario, the Company will publish the results during the week of January 10th, 2022, with a live laboratory video demonstrating real-time response of the BioCloud analyzer with the dormant SARS-CoV-2 virus. The additional testing was performed in conjunction with new interface features which were designed to be utilized and shared by researchers and applicable customers to validate the presence of the SARS-CoV-2 virus, and the level of detection response to better determine the safety of an area, and effectiveness of current site safety protocols.